AMFR

Across TCGA pan-cancer cohorts, AMFR mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of AMFR’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AMFR mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AMFR is over-expressed in tumor, although a few such as CCRCC and OV show the opposite, repressed pattern.

CCRCC, OV, and PDAC are the cancer types where AMFR tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AMFR mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.263	<.001	9	view →
OV	All	All	−0.603	<.001	2	view →
PDAC	All	III,IV	+0.563	.032	2	view →
LSCC	Female	All	+0.211	.003	2	view →
HNSC	Male	II,III,IV	−0.147	.040	2	view →
LUAD	Male	All	−0.096	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

AMFR–CCRCC

Open the CCRCC breakdown →